1. Home
  2. GSIW vs MBIO Comparison

GSIW vs MBIO Comparison

Compare GSIW & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GSIW
  • MBIO
  • Stock Information
  • Founded
  • GSIW 2016
  • MBIO 2015
  • Country
  • GSIW Hong Kong
  • MBIO United States
  • Employees
  • GSIW N/A
  • MBIO N/A
  • Industry
  • GSIW
  • MBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • GSIW
  • MBIO Health Care
  • Exchange
  • GSIW Nasdaq
  • MBIO Nasdaq
  • Market Cap
  • GSIW 8.6M
  • MBIO 7.3M
  • IPO Year
  • GSIW 2023
  • MBIO N/A
  • Fundamental
  • Price
  • GSIW $0.79
  • MBIO $2.81
  • Analyst Decision
  • GSIW
  • MBIO Strong Buy
  • Analyst Count
  • GSIW 0
  • MBIO 1
  • Target Price
  • GSIW N/A
  • MBIO $100.00
  • AVG Volume (30 Days)
  • GSIW 11.3M
  • MBIO 411.9K
  • Earning Date
  • GSIW 12-31-2024
  • MBIO 03-10-2025
  • Dividend Yield
  • GSIW N/A
  • MBIO N/A
  • EPS Growth
  • GSIW N/A
  • MBIO N/A
  • EPS
  • GSIW N/A
  • MBIO N/A
  • Revenue
  • GSIW $1,313,795.00
  • MBIO N/A
  • Revenue This Year
  • GSIW N/A
  • MBIO N/A
  • Revenue Next Year
  • GSIW N/A
  • MBIO N/A
  • P/E Ratio
  • GSIW N/A
  • MBIO N/A
  • Revenue Growth
  • GSIW N/A
  • MBIO N/A
  • 52 Week Low
  • GSIW $0.43
  • MBIO $2.71
  • 52 Week High
  • GSIW $15.45
  • MBIO $74.50
  • Technical
  • Relative Strength Index (RSI)
  • GSIW 64.32
  • MBIO 28.00
  • Support Level
  • GSIW $0.44
  • MBIO $3.96
  • Resistance Level
  • GSIW $0.51
  • MBIO $6.70
  • Average True Range (ATR)
  • GSIW 0.11
  • MBIO 0.97
  • MACD
  • GSIW 0.01
  • MBIO -0.12
  • Stochastic Oscillator
  • GSIW 43.39
  • MBIO 2.83

About GSIW Garden Stage Limited

Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: